文献速递前列腺癌

局限性与扩大盆腔淋巴结清扫在前列腺癌中的随机临床试验

Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial.
PubMed 文献 · Eur Urol Oncol · 2021-04-15

这项单中心随机试验纳入1440例拟行根治性前列腺切除术的患者,比较局限性(髂外)与扩大(髂外、闭孔及髂内)盆腔淋巴结清扫。中位随访3.1年,两组生化复发率无显著差异(HR 1.04,95%CI 0.93-1.15;p=0.5),扩大清扫未改善无生化复发。

要点

  • 扩大盆腔淋巴结清扫未降低生化复发率(HR 1.04,95%CI 0.93-1.15)
  • 两组阳性淋巴结率分别为12%与14%,差异无统计学意义
  • 2级和3级并发症发生率相似(7.3% vs 6.4%),无4-5级并发症

核心结论

  • 对于临床局限性前列腺癌,扩大盆腔淋巴结清扫相比局限性清扫未改善无生化复发。

研究设计与样本

  • 单中心随机试验,2011年10月至2017年3月入组,按外科医生每3个月整群随机分配至局限性或扩大清扫,最终分析1440例(局限性700例,扩大740例)。

主要发现

  • 局限性清扫中位淋巴结数为12枚(IQR 8-17),扩大清扫为14枚(IQR 10-20)。
  • 阳性淋巴结率局限性为12%,扩大为14%,差异-1.9%(95%CI -5.4%至1.5%;p=0.3)。
  • 中位随访3.1年,生化复发率两组无显著差异(HR 1.04,95%CI 0.93-1.15;p=0.5)。
  • 2级和3级并发症发生率局限性为7.3%,扩大为6.4%,无4级或5级并发症。

关键数值与推荐

  • 局限性清扫范围包括髂外淋巴结,扩大清扫包括髂外、闭孔及髂内淋巴结。
  • 主要终点为生化复发率。

临床怎么用

  • 在临床局限性前列腺癌中,扩大盆腔淋巴结清扫未显示生化复发获益,可考虑局限性清扫。
  • 两组淋巴结数和阳性率差异小于预期,需权衡清扫范围与分期准确性。

局限性

  • 单中心研究,整群随机设计。
  • 两组淋巴结数和阳性率差异小于预期。
  • 需开展比较盆腔淋巴结清扫与不清扫的随机试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pelvic lymph node dissection (PLND) is the most reliable procedure for lymph node staging. However, the therapeutic benefit remains unproven; although most radical prostatectomies at academic centers are accompanied by PLND, there is no consensus regarding the optimal anatomical extent of PLND. OBJECTIVE: To evaluate whether extended PLND results in a lower biochemical recurrence rate. DESIGN, SETTING, AND PARTICIPANTS: We conducted a single-center randomized trial. Patients, enrolled between October 2011 and March 2017, were scheduled to undergo radical prostatectomy and PLND. Patients were assigned to limited or extended PLND by cluster randomization. Specifically, surgeons were randomized to perform limited or extended PLND for 3-mo periods. INTERVENTION: Randomization to limited (external iliac nodes) or extended (external iliac, obturator fossa and hypogastric nodes) PLND. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the rate of biochemical recurrence. RESULTS AND LIMITATIONS: Of 1440 patients included in the final analysis, 700 were randomized to limited PLND and 740 to extended PLND. The median number of nodes retrieved was 12 (interquartile range [IQR] 8-17) for limited PLND and 14 (IQR 10-20) extended PLND; the corresponding rate of positive nodes was 12% and 14% (difference -1.9%, 95% confidence interval [CI] -5.4% to 1.5%; p = 0.3). With median follow-up of 3.1 yr, there was no significant difference in the rate of biochemical recurrence between the groups (hazard ratio 1.04, 95% CI 0.93-1.15; p = 0.5). Rates for grade 2 and 3 complications were similar at 7.3% for limited versus 6.4% for extended PLND; there were no grade 4 or 5 complications. CONCLUSIONS: Extended PLND did not improve freedom from biochemical recurrence over limited PLND for men with clinically localized prostate cancer. However, there were smaller than expected differences in nodal count and the rate of positive nodes between the two templates. A randomized trial comparing PLND to no node dissection is warranted. PATIENT SUMMARY: In this clinical trial we did not find a difference in the rate of biochemical recurrence of prostate cancer between limited and extended dissection of lymph nodes in the pelvis. This study is registered on ClinicalTrials.gov as NCT01407263.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Touijer KA, Sjoberg DD, Benfante N, et al. Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. 2021. PMID: 33865797. doi:10.1016/j.euo.2021.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。